Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Brain Neoplasms 3Neoplasm Metastasis 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Oligodendroglioma 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Breast Neoplasms 1Astrocytoma 1Adenocarcinoma of Lung 1

Interventions

Temozolomide 130Radiotherapy 86Bevacizumab 43Radiation 31Carmustine 29Irinotecan 22Erlotinib Hydrochloride 22Magnetic Resonance Spectroscopy 21Chemotherapy, Adjuvant 20Surgical Procedures, Operative 15O(6)-benzylguanine 15Carboplatin 14Radiotherapy, Intensity-Modulated 13Radiotherapy, Conformal 13sargramostim 12Sirolimus 9Imatinib Mesylate 9Filgrastim 9Drug Therapy 9temsirolimus 8Thalidomide 8Sorafenib 8Radiosurgery 8pembrolizumab 7motexafin gadolinium 7aldesleukin 7Vorinostat 7Procarbazine 7Gefitinib 7Cyclophosphamide 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gliosarcoma × efaproxiral × Clear all
NCT00005855 2013-06-21

Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
48 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡